Background and objective
Chronic inflammatory disorders after ileal pouch-anal anastomosis (IPAA) are common. These include chronic pouchitis, crohns disease (CD) of the pouch, prepouch ileitis, and rectal cuff inflammation (cuffitis). The aim of this study was to evaluate the effectiveness of biologic therapy in achieving remission in these disorders.
Method
Systematic review of all published studies from inception to April 1st, 2021 was performed to investigate the effectiveness of biologic therapies for chronic inflammatory disorders of pouch. Outcome was the efficacy of biologic therapies in achieving remission as defined by each study. A subgroup analysis was performed for each disorder separately.
Results
24 studies were identified by our search. A total of 682 patients were included in our analysis. Using a random effect model, the overall pooled efficacy of biologic therapies in achieving remission in patients with chronic inflammatory disorders of pouch was 60% (95% Confidence Interval (CI), 65 - 64). Specifically, the pooled efficacy of ustekinumab in achieving remission was 75% (95% CI, 64 - 85, p = 0.007), whereas the efficacy of vedolizumab was 60% (95% CI, 52 - 68, p = 0.172). In addition, the efficacy infliximab and adalimumab were 59% (95% CI, 53 - 64, p <0.01) and 51% (95% CI, 42 - 60, p = 0.452) respectively.
Conclusion
Ustekinumab , infliximab, vedolizumab and adalimumab are effective in achieving remission in chronic inflammatory disorders of the pouch. There is also a clear trend toward higher efficacy in patients with CD of the pouch compared to refractory pouchitis. More studies are needed to determine the efficacy of biologics in cuffitis.